Aims: To determine the comparative efficacy and safety of liraglutide and dipeptidyl
peptidase-4 (DPP-4) inhibitors as antidiabetics for Japanese patients with uncontrolled type …

Introduction Liraglutide has been widely used in the treatment of type 2 diabetes mellitus
(T2DM), however, the results of a number of randomized placebo-controlled trials on the …

Liraglutide, a glucagon-like peptide (GLP-1) receptor agonist, has showed favorable effects
in the glycaemic control and weight reduction in patients with type 2 diabetes mellitus …

Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor
agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the …

Background Agonists of the glucagon-like peptide-1 (GLP-1) receptor provide
pharmacological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors …

Background and aims Clinical trials indicate the efficacy of add-on therapy using incretin-
related drugs to treat type 2 diabetes mellitus (DM) inadequately controlled by insulin …

Background New treatments for type 2 diabetes mellitus are needed to retain insulin–
glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to …

Incretin-based therapies have been gaining much attention recently as a new class of
therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor …

Introduction As treatment agents for diabetes, liraglutide is a long-acting glucagon-like
peptide 1 receptor agonist, and dipeptidyl peptidase 4 (DPP4) inhibitors are widely used …

Objectives For people with Type 2 Diabetes Mellitus (T2DM) insufficiently controlled with
oral antidiabetic drugs (OADs), GLP-1 analogues proved to offer glycaemic control while …